Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival…
Five years after approval by the FDA and EMA, IV Benlysta remains the only drug licensed for the treatment of SLE in almost 60 years, highlighting the difficulty in successfully bringing to market…
Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At…
Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but the impact on CV risk varies by lipid disorder. Treatment has centered mainly on reducing the levels of atherogenic…
Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…
Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy…
Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant opportunities…
Beta thalassemia is a recessive monogenic blood disorder characterized by low levels or an absence of the protein ß-globin, a key component of the oxygen transporting protein hemoglobin. A lack of…
Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin),…
The biosimilars space is expected to become increasingly competitive as reference brand companies try to retain market share in the face of their product’s dwindling patent life and biosimilar…
Each year in the United States, more than 17,000 patients suffering from renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these…
Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and…
Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of
Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…